Current Report Filing (8-k)
December 04 2020 - 8:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): December 4, 2020
BRAIN
SCIENTIFIC INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
333-209325
|
|
81-0876714
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
125
Wilbur Place, Suite 170
Bohemia,
NY 11716
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (917) 388-1578
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Not
applicable
|
|
Not
applicable
|
|
Not
applicable
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01
|
Regulation FD Disclosure.
|
On
December 4, 2020, Brain Scientific Inc. (the “Company”) issued a press release announcing that it will participate
in AES2020 - the all-new virtual event for epilepsy professionals in academia, clinical practice, industry, and advocacy on December
4th-8th. The American Epilepsy Society’s Annual Meeting is the largest meeting and exhibition in the world to share common
scientific and clinical interests in epilepsy and clinical neurophysiology.
The
information in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed
to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this
Item 7.01 or Exhibit 99.1 of Item 9.01.
Item
9.01
|
Financial Statements
and Exhibits
|
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
December 4, 2020
|
BRAIN SCIENTIFIC INC.
|
|
|
|
By:
|
/s/
Boris Goldstein
|
|
Name:
|
Boris Goldstein
|
|
Title:
|
Chairman of the Board, Secretary and Executive
Vice President
|
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jul 2023 to Jul 2024